top of page

Spinal Cord Injury Investor Symposium: NervGen's CEO on how NVG-291 aims to block an inhibitor that may be preventing natural nervous system repair

Jun 26, 2024
1 min read

Mike Kelly explains the scientific rational for this peptide-based treatment, highlights its preclinical and phase 1 profile, and describes a unique P1b/2a clinical study design going forward.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page